


Claims

1. A compound of formula (I)

5




(I)

~~X is CH₃ or SO₂.~~

10 R¹ is an optionally substituted aryl or heteroaryl ring;

R² is carboxy, cyano, -C(O)CH₂OH, -CONHR³, -SO₂NHR³, tetrazol-5-yl, SO₃H, or a group of formula (VI)



(VI)

15 where R¹ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, SO₂R² where R² is alkyl, aryl, heteroaryl, or haloalkyl, or R¹ is a group -O(CH₂)_r-OOH where r is an integer of 1-8 and each R¹⁰ group is independently selected from hydrogen or alkyl; R³ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heterocycle, or a group -C(=O)R⁴ where R⁴ is hydrogen, alkyl, or aryl, or a group -P(=O)(R⁵)₂ where R⁵ is hydrogen, alkyl, or aryl.

optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkyl;

R⁴ is a group NHCOR¹⁵, NHSO₂R¹⁵ or OCONR¹⁶R¹⁷ where R¹⁵ is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R¹⁶ and R¹⁷ are

5 independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R¹⁶ or R¹⁷ is other than hydrogen, or R¹⁶ and R¹⁷ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and

10 R², R³ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R² is a group NHCOR¹⁵, R¹⁵ is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.

15

2. A compound according to claim 1 wherein a group R¹⁵, R¹⁶ and R¹⁷ as they appear in the definition of R⁴, is substituted by at least one functional group, or an aryl or heterocyclyl groups, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.

20

3. A compound according to any one of the preceding claims wherein R¹ is a group NHCOR¹⁵ or NHSO₂R¹⁵ and R¹⁵ is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.

25


4. A compound according to claim 3 wherein R¹ is alkyl substituted by a group of formula NR¹⁸R¹⁹ where R¹⁸ and R¹⁹ are independently selected from hydrogen or optionally substituted hydrocarbyl or P¹ and P² together form a heterocyclic ring which

6. A compound according to any one of the preceding claims wherein R^1 is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

7. A compound according to any one of the preceding claims where X is CH_2 .

8. A process for preparing a compound according to claim 1 which process comprises either

(a) where R^1 is $NH-COR^{1a}$ or $NHSO_2R^{1a}$, reacting a compound of formula (VII)



(VII)


where X, R^1 , R^3 , R^5 , R^6 and R^7 are as defined in claim 1, and R^2 is a group R^2 as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)


where Z is a leaving group and R^{22} is a group COR^{2a} or SO_2R^{2a} where R^{2a} is group R^2 as defined in relation to formula (I) or a precursor thereof;

or (b) where R^1 is a group $OC(=O)NR^{1a}$, reacting a compound of formula (VIA)



(VIA)

where X, R^{2'}, R¹, R³, R⁵, R⁶ and R⁷ are as defined claim 1 and R² is a group R^{2'} as defined in claim 1 or a protected form thereof, with a compound of formula (VIII A)



5

(VIII A)

where Z, R¹⁶ and R¹⁷ are as defined above;

and thereafter if desired or necessary:

- (i) converting a precursor group R^{15'} to a group R¹⁵ and/or converting a group R¹⁵ to a different such group;
 - 10 (ii) deprotecting a group R^{2'} to a group R².
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in combination with a pharmaceutically acceptable carrier.
- 15 10. A compound according to any one of claims 1 to 7 for use in the preparation of a medicament for use in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease

Application number: 09/889515

Please search:

Compounds of formula (I) in claim 1, wherein R1 is optionally substituted aryl; R2 is as defined in claim 1 except that R2 is not a group of the formula (VI); R3 is as defined in claim 1 except that R3 is not optionally substituted heterocyclyl; R4 is as defined in claim 1 except that R4 is not optionally substituted heteroaryl and at least one of R16 or R17 is other than hydrogen, and R16 and R17 do not form an optionally substituted heterocyclic ring which optionally contains further heteroatoms, together with the nitrogen atom to which they are attached; and R5, R6, and R7 are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl group.